Analysts predict that Clementia Pharmaceuticals Inc (NASDAQ:CMTA) will announce earnings per share of ($0.53) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Clementia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.54). Clementia Pharmaceuticals reported earnings per share of ($0.42) in the same quarter last year, which suggests a negative year over year growth rate of 26.2%. The company is scheduled to issue its next quarterly earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Clementia Pharmaceuticals will report full year earnings of ($1.91) per share for the current financial year, with EPS estimates ranging from ($2.15) to ($1.64). For the next fiscal year, analysts forecast that the business will report earnings of ($1.81) per share, with EPS estimates ranging from ($2.35) to ($1.22). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Clementia Pharmaceuticals.
Several analysts recently weighed in on the company. Wedbush downgraded Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Monday, February 25th. ValuEngine upgraded Clementia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Svb Leerink lowered Clementia Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $26.00 price objective on the stock. in a research report on Tuesday, February 26th. Bloom Burton lowered Clementia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 26th. Finally, Robert W. Baird lowered Clementia Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a research report on Monday, March 4th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Clementia Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.00.
Several large investors have recently bought and sold shares of CMTA. Trexquant Investment LP acquired a new stake in shares of Clementia Pharmaceuticals in the third quarter valued at approximately $126,000. JPMorgan Chase & Co. raised its position in Clementia Pharmaceuticals by 17.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,037,047 shares of the company’s stock worth $11,563,000 after purchasing an additional 155,336 shares during the period. NEA Management Company LLC raised its position in Clementia Pharmaceuticals by 26.4% in the 4th quarter. NEA Management Company LLC now owns 2,707,734 shares of the company’s stock worth $31,843,000 after purchasing an additional 566,037 shares during the period. Fosun International Ltd purchased a new position in Clementia Pharmaceuticals in the 4th quarter worth $2,627,000. Finally, Birchview Capital LP raised its position in Clementia Pharmaceuticals by 82.0% in the 4th quarter. Birchview Capital LP now owns 222,000 shares of the company’s stock worth $2,611,000 after purchasing an additional 100,000 shares during the period. Institutional investors and hedge funds own 78.72% of the company’s stock.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.